Literature DB >> 12092663

Sildenafil test: changes in the diagnostic and therapeutic management of erectile dysfunction.

P Perimenis1, A Athanasopoulos, K Gyftopoulos, G Barbalias.   

Abstract

OBJECTIVE: To assess the efficacy of sildenafil as a first-step diagnostic and therapeutic tool for erectile dysfunction (ED) and to evaluate the consequent changes in the management of male sexual insufficiency.
MATERIALS AND METHODS: Sildenafil in titrating doses up to 100 mg was prescribed to 50 men presenting to a sexual dysfunction clinic with medically documented ED. They had not undergone any specific diagnostic test before starting sildenafil.
RESULTS: Of the 50 men, 24 (48%) responded to sildenafil. Of these, 8 (33.3%) responded to 50 mg and 16 (66.7%) to 100 mg of sildenafil. Of the responders, 9 representing 18% of all studied men were discharged achieving spontaneous erections in a mean follow-up of 5.3 months. Men with no medical history, men with hypertension and men with mild coronary artery disease responded better.
CONCLUSIONS: The sildenafil test revealed that 48% of men responded to this therapy with no requirement for more invasive tests and that 18% of men required no further treatment at all. In addition this test reduced the overall cost of the diagnostic investigation. It is proposed that the sildenafil test should be used in cases with no significant medical history or in men with hypertension or mild coronary artery disease although almost all men with ED could be categorized as sildenafil-responders or sildenafil-resistant. It is also suggested that the sildenafil test would result in the ability for more men with ED to be managed exclusively in the primary care sector.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 12092663     DOI: 10.1023/a:1015278132612

Source DB:  PubMed          Journal:  Int Urol Nephrol        ISSN: 0301-1623            Impact factor:   2.370


  10 in total

1.  Oral sildenafil in the treatment of erectile dysfunction. Sildenafil Study Group.

Authors:  I Goldstein; T F Lue; H Padma-Nathan; R C Rosen; W D Steers; P A Wicker
Journal:  N Engl J Med       Date:  1998-05-14       Impact factor: 91.245

Review 2.  [Rational diagnosis of erectile dysfunction].

Authors:  E W Hauck; I Schroeder-Printzen; W Weidner
Journal:  Urologe A       Date:  1998-09       Impact factor: 0.639

3.  The international index of erectile function (IIEF): a multidimensional scale for assessment of erectile dysfunction.

Authors:  R C Rosen; A Riley; G Wagner; I H Osterloh; J Kirkpatrick; A Mishra
Journal:  Urology       Date:  1997-06       Impact factor: 2.649

4.  Sildenafil citrate after radical retropubic prostatectomy.

Authors:  B H Lowentritt; P T Scardino; B J Miles; F J Orejuela; E C Schatte; K M Slawin; S P Elliott; E D Kim
Journal:  J Urol       Date:  1999-11       Impact factor: 7.450

5.  Variable response to intracavernous prostaglandin E1 testing for erectile dysfunction.

Authors:  K Lehmann; H John; G Kacl; D Hauri; T C Gasser
Journal:  Urology       Date:  1999-09       Impact factor: 2.649

6.  Sex inventories: can questionnaires replace erectile dysfunction testing?

Authors:  D S Blander; R F Sánchez-Ortiz; G A Broderick
Journal:  Urology       Date:  1999-10       Impact factor: 2.649

7.  Sildenafil: an orally active type 5 cyclic GMP-specific phosphodiesterase inhibitor for the treatment of penile erectile dysfunction.

Authors:  M Boolell; M J Allen; S A Ballard; S Gepi-Attee; G J Muirhead; A M Naylor; I H Osterloh; C Gingell
Journal:  Int J Impot Res       Date:  1996-06       Impact factor: 2.896

8.  Treatment of erectile dysfunction with sildenafil.

Authors:  L S Marks; C Duda; F J Dorey; M L Macairan; P B Santos
Journal:  Urology       Date:  1999-01       Impact factor: 2.649

9.  Sildenafil for treatment of erectile dysfunction in men with diabetes: a randomized controlled trial. Sildenafil Diabetes Study Group.

Authors:  M S Rendell; J Rajfer; P A Wicker; M D Smith
Journal:  JAMA       Date:  1999-02-03       Impact factor: 56.272

Review 10.  Evidence based assessment of erectile dysfunction.

Authors:  G A Broderick
Journal:  Int J Impot Res       Date:  1998-05       Impact factor: 2.896

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.